Unboxing Biotech

Spectral AI’s (NASDAQ: MDAI) CEO Pete Carlson lays out the next regulatory steps for DeepView following enrollment completion in August. Data is being compiled to support a De Novo submission to the FDA by 2Q:25. See our other conversations with Spectral AI’s senior management team: https://lnkd.in/gyRiRhRe https://lnkd.in/grifCqa6 https://lnkd.in/gspJdrJE https://lnkd.in/gDs5QS6N https://lnkd.in/gmyxg7T2

Spectral AI’s (NASDAQ: MDAI) CEO Pete Carlson introduces the SnapShot M devices which is a smaller, mobile version of the DeepView diagnostic. This miniaturized version of the camera offers many applications beyond battlefield use in home health care, private practice and ambulances. See our other conversations with Spectral AI’s senior management team: https://lnkd.in/gyRiRhRe https://lnkd.in/grifCqa6 https://lnkd.in/gspJdrJE https://lnkd.in/ga4g3zpS https://lnkd.in/gDs5QS6N

Spectral AI’s (MDAI) Director of Data Science, Jihang Wang provides background on the DeepView device and how it uses multispectral imaging to diagnose burns. See our other conversations with Spectral AI’s senior management team: https://lnkd.in/gyRiRhRe https://lnkd.in/grifCqa6 https://lnkd.in/gspJdrJE https://lnkd.in/g2dyrCZd #biotechnology #research #lifescience

GeoVax Labs, Inc. Labs (NASDAQ: GOVX) is more than just a vaccine company. It is also developing a cancer drug called Gedeptin that is in Phase II clinical studies for head and neck cancer. CEO David Dodd explains that its upcoming study will be a combination trial with a checkpoint inhibitor with anticipated enrollment of 36 patients. It should begin in the second quarter of next year. See other talks in this series: https://lnkd.in/gChfA_VZ https://lnkd.in/g4MtCSCZ https://lnkd.in/gM-rbxeQ https://lnkd.in/g9G6T9hW https://lnkd.in/gChfA_VZ https://lnkd.in/g96nD4Sh https://lnkd.in/gT7V-MTq

GeoVax Labs, Inc. Labs (NASDAQ: GOVX) CEO David Dodd explains the supply situation for the smallpox and Mpox vaccine, which is now served by a single global supplier in Europe. GeoVax has secured rights from the US National Institute of Health to use the Modified Vaccinia Ankara (MVA) platform to develop a domestic version of the smallpox/Mpox vaccine and potentially assist with the global shortage of the medicine. https://lnkd.in/gKy-RyGj for more: https://lnkd.in/gChfA_VZ https://lnkd.in/g4MtCSCZ https://lnkd.in/gM-rbxeQ https://lnkd.in/g9G6T9hW https://lnkd.in/gChfA_VZ https://lnkd.in/gxUZVHKU

Unboxing Biotech Presents Lexaria Bioscience (LEXX). This short features CEO Chris Bunka who elaborates on the FDA clearance of the company's investigational new drug (IND) application. #lifesciences #lifesciencesindustry #weightloss #biotechnologyindustry https://lnkd.in/gxXiBvxG

Unboxing Biotech Presents Lexaria Bioscience (LEXX). This short features CEO Chris Bunka who enumerates the primary takeaways from the GLP-1 agonist human pilot study. https://lnkd.in/gjABQvcn #lifesciences #lifesciencesindustry #weightloss #biotechnology

Reviva Pharmaceuticals held a KOL event on February 15, 2024 which is available here in its entirety: https://lnkd.in/dAhKexnB Our short conversation with CEO Laxminarayan Bhat, Ph.D. examines the top takeaways shared in the KOL event related to the Phase III RECOVER trial which evaluated brilaroxazine in schizophrenic patients. https://lnkd.in/gRP-s26P

This segment features .Laxminarayan Bhat, Ph.D., CEO of Reviva Pharmaceuticals (NASDAQ: RVPH) and Senior Life Sciences Analyst John Vandermosten. Despite substantial progress over the last 50 years in development of treatment for schizophrenia, there remain unmet needs. Brilaroxazine has shown better safety and efficacy on several important metrics compared with approved antipsychotics. Dr. Bhat outlines several of the areas where brilaroxazine improves on standard of care #schizophrenia #biotechnology #schizophreniaawareness https://lnkd.in/gUUNdimw

This segment features .Laxminarayan Bhat, Ph.D., CEO of Reviva Pharmaceuticals (NASDAQ: RVPH) and Senior Life Sciences Analyst John Vandermosten. We cover a number of subjects related to schizophrenia medication and treatment. Starting with a review of biomarkers in development by others, we then look at biomarkers that will be used in the upcoming RECOVER 2 trial. The guests look at some of the methods of administration used for neuropsychiatric medicines. Other topics explored include treatment resistant patients, patent cliffs, pharma's search for new products, options for commercialization and expected timeline for RECOVER 2. https://lnkd.in/gxcHnN5v